. Author manuscript; available in PMC: 2009 Feb 3.

Published in final edited form as: Oncogene. 2008 Oct 20;28(2):157–169. doi: 10.1038/onc.2008.380

Table 2. Cell cycle distribution following 17-AAG treatment and CDC37 silencing.

	DMSO treated			17-AAG treated
	G1/G0	S	G2	G1/G0	S	G2
Mock	27.2 ±3.6	55.4 ±4.4	17.4 ±1.4	38.8 ±3.4	45.1 ±3.1	16.1 ±1.4
IC4	32.1 ±3.1	51.5 ±3.8	16.4 ±0.9	38.5 ±3.9	49.0 ±3.4	14.6 ±2.3
O3	33.0 ±2.0	49.0 ±1.5	18.1 ±1.1	^**63.5 ±5.	^**22.2 ±3.6	14.3 ±2.5
O4	34.9 ±2.1	46.2 ±2.2	18.9 ±0.1	^**67.2 ±1.2	^**18.5 ±3.7	14.3 ±3.8

HCT116 human colon cancer cells were treated for 24h with DMSO or 17-AAG (115nM) 72h after siRNA or mock transfection and the cell cycle distribution analysed. Mean values from 3 independent experiments are shown ± SE.

^**

p<0.01 by non-paired students t-test in comparison with DMSO treated.